Amarin's Patent Infringement Lawsuit, And Other News: The Good, Bad, And Ugly Of Biopharma

|
About: Amarin Corporation plc (AMRN), Includes: ARDS, WVE
by: Avisol Capital Partners
This article is exclusive for subscribers.
Avisol Capital Partners
Long/short equity, newsletter provider, healthcare, biotech
Summary

Amarin has a critical court date against a set of defendants in January this year.

Aridis is developing a new antibody platform.

Wave Life Sciences produces mixed results.

Amarin (AMRN) is fast approaching a significant event as the company’s lawsuit against a couple of generic drug makers is scheduled for trial on January 13, 2020. The main counter parties in this